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Edited by Lukas HuberAbstract We recently reported proliferative and anti-mineral-
ogenic eﬀects of vanadate on ﬁsh chondrocytes and here we
investigate the signalling pathways associated with these eﬀects.
Our data show that vanadate stimulates chondrocyte prolifera-
tion through the MAPK pathway, using signalling mechanisms
similar to those used by IGF-1, while it inhibits chondrocyte
diﬀerentiation/mineralization through a putative PI-3K/Ras/
Erk signalling, a pathway shared with insulin. Our data also
suggest that vanadate impairs ECM mineralization not only
by interfering with regulatory pathways but also by inhibiting
enzymatic activity of ALP. Finally, this work provides addi-
tional evidence for the conservation, throughout evolution, of
mechanisms regulating chondrocyte proliferation and diﬀerenti-
ation.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Vanadium, mostly known for enhancing mechanical proper-
ties of alloy steels in the metal industry, has also been recog-
nized as an essential trace element for biological activity in
most living animals [1]. In mammals, vanadium has been
associated to a variety of insulin-like eﬀects [2] and its action
associated to the speciﬁc regulation of protein tyrosine
phosphatases and consequent activation of tyrosine kinase
receptors, including the insulin receptor [2,3]. A role for vana-
dium in bone formation has been demonstrated [4,5] but
mechanisms of action have remained largely unexplored. In vi-
tro studies, using calvaria primary cultures [6,7] and bone-de-
rived cell lines [5,8,9], have evidenced the regulation of bone-
related enzymes activity (e.g. alkaline phosphatase (ALP)
and protein tyrosine phosphatases), the stimulation of bone-
related protein synthesis (e.g. type I collagen), the alteration
of bone-related cell proliferation and extracellular matrixAbbreviations: ALP, alkaline phosphatase; ECM, extracellular matrix;
IGF-1, insulin-like growth factor 1; MAPK, mitogen-activated protein
kinase; PI-3K, phosphatidyl inositol-3 kinase
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lin-like growth factor 1 (IGF-1) signalling mechanisms [5,9] by
vanadium compounds. However, there is still much to unveil
in order to understand vanadium mechanisms of action in
bone.
In this study, wortmannin, a speciﬁc inhibitor of phosphati-
dyl inositol-3 kinase (PI-3K) pathway, and PD98059, a speciﬁc
inhibitor of mitogen-activated protein kinase (MAPK) have
been tested for their eﬀects on vanadium-associated alteration
of growth performances, ECM mineralization, ALP activity,
collagen synthesis in VSa13 cells.2. Materials and methods
2.1. Cell culture and ECM mineralization
VSa13 cells were cultured as described previously [10]. ECM miner-
alization was induced in conﬂuent cultures by supplementing medium
with 50 lg/ml of L-ascorbic acid, 10 mM b-glycerophosphate and
4 mM CaCl2. At appropriate times, mineral deposition was revealed
using the von Kossa staining method and quantiﬁed by densitometric
analysis [10]. Culture medium was renewed every 2 days in prolifera-
tion experiments and every 3.5 days in mineralization experiments.
Insulin (1–100 nM), IGF-1 (1–100 nM) and vanadate (2.5–7.5 lM)
treatments were applied at the time of medium renewal.2.2. Preparation of vanadate, PD98059, wortmannin, insulin and IGF-1
stock solutions
Vanadate solution (50 mM, pH 6–7) was prepared as described pre-
viously [8]. PD98059 and wortmannin were solubilised in DMSO at 6
and 10 mg/ml, respectively. Bovine insulin (Sigma–Aldrich) and Pag-
rus auratus IGF-1 (Novozymes GroPep) were solubilised in pH 2 water
at 10 lM and in pH 6 water at 0.1 mg/ml, respectively. Milli-Q water
(Millipore) was used to prepare vanadate, insulin and IGF-1 solutions.2.3. Measurement of cell proliferation
VSa13 cell proliferation was determined from cultures seeded in 96-
well plates at 1.5 · 103 cells/well using the CellTiter 96 non-radioactive
proliferation assay kit (Promega). At appropriate times, cells were
incubated for 1 h with 20 ll of reagent mixture then cell proliferation
was determined from absorbance at 490 nm.2.4. Measurement of ALP activity
VSa13 cells grown for 4 weeks under mineralizing conditions were
washed three times with phosphate-buﬀered saline (PBS), scrapped
oﬀ the plate into 500 ll of 0.1% Triton X-100 then centrifuged for
1 min at 16000 · g. ALP activity was determined at 37 C from initial
rates of p-nitrophenyl phosphate (p-NPP) hydrolysis into p-nitrophe-
nol (p-NP). Formation of p-NP was monitored at 405 nm from the fol-
lowing reaction mixture: 800 ll of reaction buﬀer (55 mM glycine and
0.55 mM MgCl2 at pH 10.5), 100 ll of 5 mM p-NPP and 100 ll of cell
extract supernatant. ALP activity was normalized with protein content
determined using Bradford reagent (Bio-Rad).ation of European Biochemical Societies.
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VSa13 cells grown for 4 weeks under mineralizing conditions were
washed three times with PBS then stained with Sirius red dye
(F3BA; Chroma) as described previously [11]. Bound dye was solubi-
lised into 200 ll of 0.1 N NaOH and collagen content was determined
from absorbance at 550 nm.
2.6. Statistical analysis
Values are the mean of at least three separate experiments and are
presented with their standard deviation. Diﬀerences upon treatment
were analyzed by one-way ANOVA and considered signiﬁcant at
P < 0.05.3. Results and discussion
In vitro studies investigating vanadium insulin-like eﬀects
and speciﬁc targets in bone have been largely restricted to a
particular taxonomic group (i.e. mammals) and to particular
cell types (i.e. osteoblast-like and osteosarcoma cells). This
work evidences, for the ﬁrst time in a non-mammalian
in vitro system and using a chondrocyte-like cell line, the role
of MAPK and PI-3K pathways in the mediation of vanadate
eﬀects on proliferation and mineralization.
3.1. MAPK pathway mediates vanadate stimulation of VSa13
cell proliferation
Vanadate (2.5–7.5 lM), insulin (1–100 nM) and IGF-1 (1–
100 nM) were tested for their eﬀect on VSa13 cell growth. Both
vanadate and IGF-1, but not insulin, stimulated cell prolifera-
tion to a similar extent (strongest stimulation at 7.5 lM and
10 nM, respectively; Supplementary Figures 1 and 2 and
Fig. 1). Wortmannin and PD98059, known inhibitors of
PI-3K and MAPK pathways, respectively, were then tested
for their eﬀect on VSa13 cell proliferation and for their capac-
ity of reverting IGF-1 and vanadate stimulatory eﬀects. Divid-Fig. 1. Eﬀect of vanadate, insulin, IGF-1, wortmannin and PD98059 on V
1.5 · 103 cells/well then either left untreated or treated with PD98059, wor
proliferation was evaluated after 8 days using MTS assay. Asterisk indica
P < 0.05; one-way ANOVA).ing cultures of VSa13 cells were treated for 8 days with 0.1 lM
wortmannin, 100 lM PD98059 (non-toxic concentrations,
data not shown) in the presence or absence of insulin, vanadate
or IGF-1 (Fig. 1). PD98059, but not wortmannin, totally abol-
ished vanadate and IGF-1 stimulation of cell proliferation
(inhibitors alone had no eﬀect) suggesting that proliferation
of VSa13 cells is stimulated by vanadate through the activation
of the MAPK pathway. A similar contribution of the MAPK
pathway in the transduction of vanadate proliferative eﬀect
has been reported in mammalian osteoblast-like cells [12,13],
suggesting a conservation of mechanisms of action throughout
evolution and across bone cell types. The inability of insulin to
enhance VSa13 cell proliferation suggests that the activation of
MAPK pathway by vanadate would occur through an insulin
receptor-independent manner. Similarly, the stimulation of
VSa13 cell proliferation by IGF-1 through MAPK pathway
and to a similar extent, suggest that the activation of MAPK
pathway by vanadate could occur through IGF-1 receptor
and/or signalling pathway, although we cannot exclude that
other tyrosine kinase receptors (e.g. platelet-derived growth
factor (PDGF) receptor) may be involved [5]. Similar mecha-
nisms (i.e. those related to the proliferative eﬀect of IGF-1)
have been recently reported in the mouse chondrocyte ATDC5
cell line [14] and thus, based on those results as well as our data
reported in this study, we propose the existence of a mecha-
nism involving MAPK pathway that would regulate chondro-
cyte proliferation and transduce vanadate eﬀect (Fig. 5A).3.2. Putative PI-3K/Ras/Erk pathway mediates vanadate
impairment of VSa13 ECM mineralization
Wortmannin and PD98059 were then tested for their eﬀect
on VSa13 ECMmineralization and for their capacity of revert-
ing vanadate and insulin inhibitory eﬀects previously demon-
strated [8] and further conﬁrmed here. Mineralizing VSa13Sa13 cell proliferation. VSa13 cells were seeded in 96-well plates at
tmannin, vanadate, insulin or IGF-1, alone or in combinations. Cell
tes values statistically diﬀerent from corresponding controls (n P 3;
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100 lM PD98059, 10 nM IGF-1, 10 nM insulin, and/or 5 lM
vanadate, then evaluated for mineralization. While unaltered
by IGF-1, mineral deposition was increasingly impaired by
insulin (1.4-fold), vanadate (8-folds) and almost abolished by
a combination of both agents (Fig. 2). Apparent synergy be-
tween vanadate and insulin could suggest that diﬀerent signal-
ling pathways are involved in both mechanisms of action, or
that vanadate potentiates insulin action during mineralization,
e.g. by inhibiting PTPases, therefore increasing sensitivity of
insulin pathway as previously suggested [15]. Interestingly,
ECM of PD98059-treated cells, but not that of wortmannin-
treated cells, exhibited a signiﬁcant increase in mineral deposi-
tion (3.2-folds), suggesting a down-regulation of ECM
mineralization by MAPK pathway. We propose, in agreement
with recent results obtained in mouse ATDC5 chondrocyte
cells [14,16], that MAPK pathway may aﬀect ECM mineraliza-
tion of VSa13 cells by inhibiting cell diﬀerentiation. The role of
MAPK pathway in regulating VSa13 ECM mineralization was
further conﬁrmed by the reversion (100% and 72.5%, respec-
tively) of insulin and vanadate anti-mineralogenic eﬀects with
PD98059. Surprisingly, wortmannin also reverted (100% and
57.5%, respectively) insulin and vanadate anti-mineralogenic
eﬀects, suggesting a role for PI-3K pathway in regulating
VSa13 ECM mineralization. As expected, impairment of min-
eralization by the combined eﬀects of insulin and vanadate was
reverted to an extent similar to that observed for vanadate
alone. Altogether, these results suggest that both MAPK and
PI-3K pathways could mediate vanadate and insulin anti-min-
eralogenic eﬀects. We propose that regulation of VSa13 cell
diﬀerentiation/mineralization is exerted through the PI-3K/
Ras/Erk pathway (a combination of MAPK and PI-3K path-
ways), a ﬁnding that is in agreement with recent results ob-Fig. 2. Eﬀect of IGF-1, vanadate, insulin, wortmannin and PD98059 on VS
2 · 104 cells/well, grown until conﬂuence then treated for mineralization. M
insulin, vanadate, PD98059, or wortmannin, alone or in combinations. Min
evaluated by densitometry analysis. Mineralization data are presented as the
treated, treated with wortmannin and treated with PD98059). Asterisk indic
P < 0.05; one-way ANOVA).tained for mouse MC3T3-E1 cells [17]. We further propose,
based on overall available data as well as results reported in
this study, that a similar mechanism is responsible for trans-
ducing vanadate eﬀects (Fig. 5B). However, incomplete rever-
sion of vanadate anti-mineralogenic eﬀect by both PD98059
and wortmannin (83.2% reversion, result not shown) suggests
that other diﬀerentiation/mineralization-related mechanisms
are aﬀected by vanadate. ALP, by cleaving pyrophosphate,
an inhibitor of ECM mineralization [18], and collagen, an
essential structural component of ECM [19], were considered
as putative targets for vanadate action and further investi-
gated.
3.3. ALP activity is inhibited while collagen content is increased
by micromolar concentrations of vanadate
Enzymatic activity of ALP was ﬁrst determined in mineral-
ized cell cultures treated with 5 lM vanadate and/or 10 nM
insulin. Interestingly, a 40% increase in ALP activity was ob-
served following ECM mineralization, while activity remained
similar to non-mineralizing control cells upon vanadate treat-
ment (Fig. 3). In similar experiments, collagen content was
shown to increase by 57% in mineralized cultures and by an
additional 17% when those cultures were also treated with van-
adate (Fig. 4). The stimulation of both ALP activity and colla-
gen production in mineralized cultures is consistent with their
role in mineralization mechanisms. The inability of insulin to
aﬀect ALP activity and collagen production suggests that van-
adate action occurs through an insulin receptor-independent
manner. ALP activity was then measured in cellular extracts
of mineralized cultures (4 weeks) in the presence of increasing
concentrations of vanadate: activity was stimulated at low con-
centration (5 lM) while strongly inhibited at higher concentra-
tions (from 25 to 500 lM) of vanadate. We propose, ina13 ECM mineralization. VSa13 cells were seeded in 24-well plates at
ineralizing cultures were then left untreated or treated with IGF-1,
eral deposition was revealed after 4 weeks by von Kossa staining and
ratio between individual values and their corresponding controls (non-
ates values statistically diﬀerent from corresponding controls (n P 3;
Fig. 3. ALP activity in mineralized cell cultures treated with insulin and vanadate. VSa13 cells were seeded in 24-well plates at 2 · 104 cells/well,
grown until conﬂuence then treated for mineralization. Mineralizing cultures were then left untreated (control) or treated with insulin and/or
vanadate. ALP activity was measured in cell extracts after 4 weeks of treatment (left panel) or assayed in the presence of increasing concentration of
vanadate (right panel; values are normalized with ALP activity measured in the absence of vanadate). Asterisk indicates values statistically diﬀerent
from corresponding controls (n P 3; P < 0.05; one-way ANOVA).
Fig. 4. Collagen content in mineralized cell cultures treated with
insulin and/or vanadate. VSa13 cells were seeded in 24-well plates at
2 · 104 cells/well, grown until conﬂuence then treated for mineraliza-
tion. Mineralizing cultures were then left untreated (control) or treated
with insulin and/or vanadate. Total collagen content was determined
after 4 weeks of treatment through Sirius red staining. Asterisk
indicates values statistically diﬀerent from corresponding controls
(n P 3; P < 0.05; one-way ANOVA).
Fig. 5. Putative mechanisms of action for insulin, IGF-1 and vanadate in ver
ATDC5 and VSa13 cell lines, respectively. Black, gray and dashed arrows indi
respectively. X indicates an absence of eﬀect. V, vanadate. Raf, Mek and Er
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of vanadium in VSa13 cells [8], that although cultures were
treated with non-inhibitory concentrations of vanadate, these
may accumulate intracellularly and reach concentrations
inhibitory for ALP activity therefore aﬀecting mechanisms of
ECMmineralization. On the contrary, the increase of total col-
lagen content in vanadate-treated mineralized cultures (most
probably the result of increased type X collagen as observed
in diﬀerentiating ATDC5 chondrocyte cells [16]) can hardly ex-
plain the decrease of ECM mineralization since increased col-
lagen production is rather likely to beneﬁt ECM
mineralization. Similar results (i.e. inhibition of ALP activity
and/or stimulation of collagen synthesis) have been reported
in chicken [7] and mouse [6,12,20] bone-derived systems, sug-
gesting once again a conservation of mechanisms throughout
evolution and across bone cell types.4. Conclusions
Various evidences have been collected during this work to-
wards the involvement of MAPK and PI-3K/Ras/Erk path-tebrate chondrocyte cells. Circled 5 and 13 indicate pathways related to
cate activated, moderately activated and putatively activated pathways,
k are intermediates in the MAPK pathway.
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respectively, using a ﬁsh bone-derived cell line of the chondro-
cyte lineage. We propose that vanadate shares with IGF-1 the
signalling pathway regulating chondrocyte proliferation, while
it shares with insulin the signalling pathway regulating chon-
drocyte diﬀerentiation/mineralization. We also propose that
vanadate not only aﬀects ECM mineralization by activating
the PI-3K/Ras/Erk pathway but also inhibits the enzymatic
activity of ALP. Finally, this work provides strong evidence
for the conservation, throughout evolution, of those mecha-
nisms regulating chondrocyte proliferation and diﬀerentiation,
emphasizing the suitability of ﬁsh to investigate vertebrate
development, in particular mechanisms related to chondrogen-
esis.
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